Molecular Classification of Erythrodermas Based on a Molecular Classifier

Molecular Classification of Erythrodermas Based on a Molecular Classifier - MoEr

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039663

Enrollment

Registered

2026-03-26

Start date

2026-03-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L26

Interventions

Group 1: This is a non-interventional, diagnostic multicenter study conducted at the study sites Freiburg and Augsburg. The aim is to evaluate the molecular classifier for the precise classification o

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Diagnosis of erythroderma (clinical involvement of >90% of the body surface area) with suspected psoriasis, eczema, or other differential diagnoses, persisting for >4 weeks - Skin biopsy performed at the time of diagnosis, with optional follow-up biopsies under targeted therapy (e.g., biologic therapy) for psoriasis/eczema - Written informed consent for the use of residual tissue material obtained during routine diagnostic procedures

Exclusion criteria

Exclusion criteria: - Erythroderma <4 weeks in duration or known alternative cause (e.g., drug eruption, contact dermatitis) - Lack of informed consent - Insufficient tissue material for molecular classifier analysis

Design outcomes

Primary

Measure	Time frame
The aim of the present study is to achieve a precise classification of the underlying skin disease in patients with erythroderma based on the inflammatory profile. The use of molecular diagnostics is expected to enable a more accurate differentiation than is possible with clinical or histopathological methods alone.	—

Secondary

Measure	Time frame
The study analyzes discrepancies between conventional histopathology and the molecular classifier, as well as their agreement with clinical and final diagnoses. In addition, interobserver variability among three blinded dermatopathologists is assessed based on predefined histological features. In the retrospective part, therapeutic response is evaluated in relation to the final diagnosis. Furthermore, individual case analyses of unclear cases are performed, and the proportion of undetermined results is quantified as a potential indicator of alternative pathogenic mechanisms.	—

Measure

Time frame

The study analyzes discrepancies between conventional histopathology and the molecular classifier, as well as their agreement with clinical and final diagnoses. In addition, interobserver variability among three blinded dermatopathologists is assessed based on predefined histological features. In the retrospective part, therapeutic response is evaluated in relation to the final diagnosis. Furthermore, individual case analyses of unclear cases are performed, and the proportion of undetermined results is quantified as a potential indicator of alternative pathogenic mechanisms.

—

Countries

Germany

Contacts

Public ContactKarisa Thölken

Klinik. für Dermatologie

derma.studien@uk-augsburg.de+49 0821 400-7421

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026